Subscribe to MDT Magazine News

GenMark Diagnostics dismisses patent lawsuit against Caliper Life Sciences, Inc

March 2, 2011 7:38 pm | by I-Micronews | Comments

GenMark Diagnostics Inc. (NASDAQ:GNMK) announced today that it has dismissed a lawsuit in the Northern District of California pending since November 2010 that requested declaratory relief that it does not infringe three U.S. patents on microfluidic technology allegedly owned by Caliper...

Reprogrammed Cells Are Rife with Genetic Mutations

March 2, 2011 7:37 pm | by Massachusetts Institute of Technology | Comments

Before these cells can be used for therapy, scientists need to better understand how reprogramming affects the genome.

Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia

March 2, 2011 7:35 pm | by Bio-Medicine.Org | Comments

NEW YORK and OSAKA, Japan, March 2, 2011 /- Intra-Cellular Therapies, Inc. ("ITI") and Takeda Pharmaceutical Company Limited (TSE: 4502, "Takeda"), today announced that they have entered into an exclusive collaboration to develop and commercialize selective phosphodiesterase type 1 (PDE1)...


LHC 4Q profit drops with reimbursement cut

March 2, 2011 1:45 pm | by The Associated Press | Comments

Home health provider LHC Group Inc. recorded a 10 percent drop in fourth-quarter profit as the federal government cut Medicare reimbursements, the company reported Wednesday.For the October-through-December period, LHC Group earned $11.4 million, or 63 cents per share, on revenue of $168.1...

Meridian gets new clearance for bacterium test

March 2, 2011 1:45 pm | by The Associated Press | Comments

Meridian Bioscience Inc. said Wednesday that it received clearance for a pediatric claim on its illumigene C. difficile test.The test detects toxigenic strains of C. difficile, a bacterium that can cause diarrhea and colon inflammation. The company said the Food and Drug Administration gave the...

Researchers Predict Age of T Cells to Improve Cancer Treatment

March 2, 2011 12:36 pm | by Georgia Tech Institute of Technology | Comments

Researchers are accurately predicting T cell age and quality in order to improve the effectiveness of the cancer therapy known as adoptive T cell transfer, which is currently limited by the cells' finite lifespan.

WellPoint sees strong enrollment in big accounts

March 2, 2011 11:45 am | by The Associated Press | Comments

WellPoint Inc. has already more than doubled the enrollment gains it expected in 2011 for national accounts that the health insurer administers for large employers.The Indianapolis company, which operates Blue Cross Blue Shield plans in 14 states, expected to gain about 200,000 people from that...

Replacement execution drug ample, but has issues

March 2, 2011 10:45 am | by GREG BLUESTEIN - Associated Press - Associated Press | Comments

The drug that states are increasingly counting on to replace a sedative used in executions shares several drawbacks with the one that's no longer readily available.But there's one key difference: Experts say there's plenty of the replacement — a drug called pentobarbital. And it's not likely...


Fighting cancer at your local Indian restaurant

March 2, 2011 10:38 am | by EurekAlert | Comments

(American Friends of Tel Aviv University) Dr. Shahar Lev-Ari of the Sackler Faculty of Medicine at Tel Aviv University has found that curcumin, an ingredient found in turmeric -- a bright yellow spice from south Asia and the main ingredient in curries -- can fight cancer when used...


Insulet signs insulin device distribution deal with GSK

March 2, 2011 9:38 am | by Mass High Tech: The Journal of New England Technology | Comments

Bedford-based medical device maker Insulet Corp. has signed an exclusive distribution agreement with GlaxoSmithKline Inc. in Canada. The deal relates to Insulet's OmniPod Insulin Management System.

New NeuroPhage funding to back move to Alzheimer's trial

March 2, 2011 9:37 am | by Mass High Tech: The Journal of New England Technology | Comments

NeuroPhage Pharmaceuticals Inc., which closed a $12.4M Series B round Tuesday, said that it plans to use the funds to get its lead compound to treat Alzheimer's disease, NPT001, into a Phase 1 clinical trial in about a year and a half.

$3.6 million research project underway to reduce mother and baby deaths in Malawi

March 2, 2011 8:37 am | by EurekAlert | Comments

(University of Warwick) Warwick Medical School has just begun a ?2.6 ($3.6) million three year research and training program to train Malawian clinical officers in a bid to reduce the country's high death rate for pregnant mothers and babies.


Accretive Health 4th-quarter profit surges

March 2, 2011 7:45 am | by The Associated Press | Comments

Accretive Health Inc., which helps hospital systems manage their revenue cycles, said Wednesday its fourth-quarter profit more than doubled on higher services revenue.Accretive said its net income rose to $5.5 million, or 6 cents per share, up from $2.3 million, or 5 cents per share, during the...

FDA CONSUMER HEALTH INFORMATION - FDA Intends to Remove Unapproved Drugs From Market

March 2, 2011 7:35 am | by Bio-Medicine.Org | Comments

SILVER SPRING, Md., March 2, 2011 /PRNewswire-USNewswire/ -- Do you use a prescription cough, cold, or allergy relief drug? (Logo: ) Federal regulators aim to take certain unapproved prescription medicines intended to relieve cough, cold,...


FDA Prompts Removal of Unapproved Drugs From Market

March 2, 2011 6:39 am | by Bio-Medicine.Org | Comments

SILVER SPRING, Md., March 2, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today took action against companies that manufacture, distribute, or market certain unapproved prescription oral cough, cold, and allergy products. The affected products cannot be legally...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.